MET and non-small cell lung carcinoma: In 2023, glumetinib (9) received approval from the National Medical Products Administration (NMPA) for commercial distribution as a therapeutic agent for adult patients diagnosed with locally advanced or metastatic NSCLC characterized by MET exon 14 skipping mutations (Halder et al., 2024).